These Neuro-SysMed trials are currently recruiting patients. Contact information is included on each page if you click the name of the trial.
Parkinson’s disease (PD)
A placebo-controlled trial to study whether treatment with nicotinamide riboside (NR) protects the neural cells and delays disease progression in Parkinson’s disease. NR increases the levels of NAD, which is favorable for the energy translation and survival in human cells. If the results are positive, the study will enable new treatment that can delay Parkinson’s disease.
STRAT-PARK is a cohort study with the purpose of understanding the causes of Parkinson’s disease and group patients with Parkinson’s disease according to cause, so that custom treatment can be given. We need to recruit 1500 patients with Parkinson’s disease and 500 healthy people as controls. Participants will receieve regular follow-up with medical and genetic examinations. STRAT-PARK will open the way for personalized treatement for Parkinson’s disease.
Multiple sclerosis (MS)
RAM-MS has as its purpose to study whether there is a difference in treatment effect, safety and cost between autolog stem cell transplants (bone marrow transplants) and the most effective approved MS medication (alemtuzumab and kladribin).
The aim of the study is to examine wheter Rituksimab has comparable effect and side-effects to Okrelizumab, as well as studying the effect of treatment from disease debut. If the effect is comparable, we can offer highly effective treatment as soon as the diagnosis is established.
Amyotrophic lateral sclerosis (ALS)
NO-ALS is a placebo controlled trial that examines whether nicotinamide riboside (NR) combined with pterostilbene delays disease progression in ALS. Participants get active medication or placebo for one year. The trial recruits patients across Norway and plans to complete in 2023. If the effect is weak, 180 patients will be needed to conclude. If it is strong, 90 patients will be enough. An open extension of the study has now been approved, and all participants will be offered to continue on active medication. With this extension, all patients will be offered one year of treatment after one year in the NO-ALS trial. We hope this will motivate patients to participate in the trial. It is an approach for quickly discovering whether the treatment is effective.
STRAT-COG is a cohort trial that attempts to understand dementia disease and group people that suffer from dementia based on root cause, such that tailored treatment is possible. We aim to recruit several hundred dementia patients and healthy controls. Participants will be followed up with medical and molecular examinations. STRAT-COG will open the way for better diagnostics and treatment for patients with dementia.